Looks like you’re on the UK site. Choose another location to see content specific to your location
Shire and Novimmune ally on development of haemophilia A therapy
Shire has announced a new collaboration with Novimmune on the development of a bispecific antibody therapy for haemophilia A.
Under the terms of the agreement, Shire will gain exclusive worldwide rights to develop and commercialise the bispecific antibody, which is currently in preclinical development for the treatment of haemophilia A and haemophilia A patients with inhibitors.
Shire will lead the development of the program to optimise and evaluate a fully-human, bispecific IgG antibody targeting FIXa and FX, which will function by imitating the body's natural mechanism of Factor VIII-driven coagulation.
It is hoped that this will result in the creation of a new treatment that improves upon the established long-term record of efficacy and safety that has been set by the Factor class.
Fritz Scheiflinger, head of global research at Shire, said: "We are encouraged by the potential of the data that we have seen in early discovery and the promise it may hold for haemophilia A patients and patients with inhibitors."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard